Elevation Oncology CMO Valerie Jansen departs; severance includes 9-month salary and equity vesting

Elevation Oncology, Inc.

CMO Valerie Jansen stepped down effective March 31, 2025.
Separation agreement provides lump-sum payment equal to 9 months of salary.
COBRA premium reimbursement for up to 9 months post-separation.
Accelerated vesting of equity awards for shares that would have vested over 9 months.
No successor CMO named; company has not disclosed a replacement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Valerie M. Jansen

Chief Medical Officer

Elevation Oncology, Inc.

Effective: 2025-03-31
Filed: April 1, 2025, 7:59 PM ET

agreed that Dr. Jansen would step down as Chief Medical Officer effective March 31, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Valerie M. Jansen departed as Chief Medical Officer at Elevation Oncology, Inc..

Action: stepped down
Role: Chief Medical Officer

Exact text from the filing

agreed that Dr. Jansen would step down as Chief Medical Officer effective March 31, 2025

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-25-004266

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.